Profile: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

9.53EUR
17 Apr 2015
Change (% chg)

€-0.02 (-0.19%)
Prev Close
€9.55
Open
€9.58
Day's High
€9.66
Day's Low
€9.50
Volume
197,734
Avg. Vol
191,466
52-wk High
€11.48
52-wk Low
€7.40

Search Stocks
Ablynx NV is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments, for a range of human diseases, including inflammation, haematology, oncology and pulmonary disease. The Company has approximately 25 programs in the pipeline and seven Nanobodies are in clinical development. The Company has ongoing research collaborations and partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.

Company Address

Ablynx NV

Technologiepark 21, Zwijnaarde
GENT     9052
P: +329.2620000
F: +329.2620001

Company Web Links

Search Stocks